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Background
Multicentric Castleman’s disease (MCD), which has
been associated with human herpesvirus-8 (HHV-8), is a
lymphoproliferative disorder with an increased preva-
lence in HIV positive patients [1]. We describe our
experience with MCD in a group of patients with
HIV/AIDS in an urban HIV clinic.
Methods
Our clinic serves annually 5,000 patients diagnosed with
AIDS. Patients with a diagnosis of multicentric Castle-
man’s disease between 2006 and 2010 were identified
from the pathology database at Grady Memorial Hospital
or referrals to the clinic. Clinic charts and medical
records were abstracted. Patients’ demographics, CD4
counts, HIV viral load, HIV and MCD treatment and
outcomes were recorded.
Results
Nine patients diagnosed with MCD were identified in our
HIV/AIDS population. All patients were male and
reported sex with men (MSM) as their risk for HIV infec-
tion. The mean age at MCD diagnosis was 39.22 ± 11.40;
the mean CD4 cell count nadir was 68.33 ± 62.2 cells/
mm
3. 85% (7/9) were on cART (combined antiretroviral
therapy) at the time of MCD diagnosis with a mean CD4
count of 233.67±157.44 cells/mm
3. MCD was of the hya-
line vascular variant in 3 patients, plasma cell variant in 2,
transitional in 1 patient, and unspecified in 2 patients.
Systemic symptoms were present in three patients. Five
patients had both Kaposi sarcoma (KS) and MCD (2 with
KS occurring after MCD diagnosis, 1 with KS before
MCD, 2 with KS and MCD diagnosed simultaneously).
Most of the patients were anemic with mean hemoglobin
of 8.99±4.04 g/dL and hypoalbuminemic (2.31±0.96). 85%
had anemia, hepatosplenomegaly, and low albumin at
diagnosis. Treatment consisted of valgancyclovir, che-
motherapy and/or rituximab. In the 5 patients who died,
the mean time from MCD diagnosis was 425.2±447 days.
Conclusions
HIV-associated MCD is characterized by lymphadenopa-
thy, splenomegaly, anemia and hypoalbuminemia.
Among the diseases associated with HHV8 (KS, primary
effusion lymphoma, and MCD), MCD appears to be the
least affected by cART use or degree of immunosup-
pression [2]. In our cohort, 85% of patients had a CD4
count above 200 at MCD diagnosis.The survival with
cART is still dismal, with one year survival of 50%. Lar-
ger multicenter study is needed to better understand the
pathogenesis of HIV-associated MCD and its treatment.
Author details
1Winship Cancer Institute, Emory University, Atlanta, GA, USA.
2Division of
Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
3Infectious Disease Program, Grady Health System, Atlanta, GA, USA.
4Department of Pathology, Emory University School of Medicine, Atlanta, GA,
USA.
Published: 19 April 2012
References
1. Powles T, Stebbing J, Bazeos A, et al: The role of immunosuppresssion
and HHV-8 in the increasing incidence of HIV-associated multicentric
Castleman’s disease. Ann Oncol 2009, 20(4):775-9.
2. Myelona EE, Baraboutis IG, Lekakis LJ, et al: Multicentric Castleman’s
disease in HIV infection: a systematic review of the literature. AIDS Rev
2008, 10(1):25-35.
* Correspondence: rnpilla@emory.edu
1Winship Cancer Institute, Emory University, Atlanta, GA, USA
Full list of author information is available at the end of the article
Pillai et al. Infectious Agents and Cancer 2012, 7(Suppl 1):P20
http://www.infectagentscancer.com/content/7/S1/P20
© 2012 Pillai et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.doi:10.1186/1750-9378-7-S1-P20
Cite this article as: Pillai et al.: Multicentric Castleman’s disease in HIV/
AIDS patients at an urban HIV clinic in Atlanta, Georgia, in the combined
antiretroviral therapy era. Infectious Agents and Cancer 2012 7(Suppl 1):P20.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pillai et al. Infectious Agents and Cancer 2012, 7(Suppl 1):P20
http://www.infectagentscancer.com/content/7/S1/P20
Page 2 of 2